Compare NBHC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | IOVA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2011 | 2008 |
| Metric | NBHC | IOVA |
|---|---|---|
| Price | $44.04 | $4.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $47.67 | $9.00 |
| AVG Volume (30 Days) | 433.0K | ★ 14.1M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $47,100,000.00 | N/A |
| Revenue This Year | $39.96 | $47.74 |
| Revenue Next Year | $7.14 | $40.31 |
| P/E Ratio | $96.76 | ★ N/A |
| Revenue Growth | ★ 2.86 | N/A |
| 52 Week Low | $35.06 | $1.70 |
| 52 Week High | $45.63 | $5.63 |
| Indicator | NBHC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 56.87 |
| Support Level | $40.68 | $2.07 |
| Resistance Level | N/A | $4.35 |
| Average True Range (ATR) | 0.98 | 0.33 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 72.88 | 55.29 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.